Medical Research & Biometrics Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 102300.
J Tradit Chin Med. 2022 Aug;42(4):487-492. doi: 10.19852/j.cnki.jtcm.2022.04.001.
To summarize and evaluate the effectiveness and safety of Redcore lotion on treating vulvovaginal candidiasis (VVC) using a systematic review and Meta-analysis of randomized controlled trials.
A systematic literature search was performed in five English and three Chinese electronic databases up to October 2019. Randomized controlled trials in the treatment for VVC were included; only studies which compared the effectiveness and safety of Redcore lotion plus miconazole with miconazole alone were included. Relative risk (RR) and 95% confidence intervals (CI) were used in the Meta-analysis.
Seven studies involving 768 patients suffering from VVC were identified; 468 of the patients were pregnant women (60.9%). Combination group (Redcore lotion plus miconazole) was more effective in reduCIng symptomatic episodes of VVC than miconazole alone, with respect to cure rate (RR, 1.31; 95% CI, 1.09-1.57; P = 0.01), fungal culture negative rate (RR, 1.21; 95% CI, 1.04-1.41; P = 0.01), and effective rate (RR, 1.18; 95% CI, 1.05-1.35; P = 0.01). Subgroup analyses for pregnant women also showed that the combination group had superior outcomes with respect to VVC cure rate (RR, 1.48; 95% CI, 1.16-1.88, P < 0.01), fungal culture negative rate (RR, 1.26; 95% CI; 1.09-1.47; P < 0.01), and effective rate (RR, 1.25; 95% CI, 1.10-1.42; P < 0.01). Additionally, the observed risk of adverse events was lower in the combination medication group (RR, 0.30; 95% CI, 0.14-0.65; P < 0.01).
Though overall quality of individual studies was low, Redcore lotion plus miconazole can significantly improve clinical effectiveness and safety compared with miconazole alone.
通过系统评价和 Meta 分析,总结和评估 Redcore 洗剂治疗外阴阴道念珠菌病(VVC)的有效性和安全性。
系统检索了截至 2019 年 10 月的五个英文和三个中文电子数据库中的文献。纳入治疗 VVC 的随机对照试验;仅纳入比较 Redcore 洗剂联合咪康唑与咪康唑单独治疗有效性和安全性的研究。Meta 分析采用相对危险度(RR)和 95%置信区间(CI)。
共纳入 7 项研究,涉及 768 例 VVC 患者,其中 468 例为孕妇(60.9%)。与咪康唑单独治疗相比,联合组(Redcore 洗剂联合咪康唑)在降低 VVC 症状发作方面更有效,治愈率(RR,1.31;95%CI,1.09-1.57;P=0.01)、真菌培养阴性率(RR,1.21;95%CI,1.04-1.41;P=0.01)和有效率(RR,1.18;95%CI,1.05-1.35;P=0.01)均较高。对于孕妇的亚组分析也显示,联合组在 VVC 治愈率(RR,1.48;95%CI,1.16-1.88,P<0.01)、真菌培养阴性率(RR,1.26;95%CI;1.09-1.47;P<0.01)和有效率(RR,1.25;95%CI,1.10-1.42;P<0.01)方面均有更好的结果。此外,联合用药组不良反应风险较低(RR,0.30;95%CI,0.14-0.65;P<0.01)。
尽管个别研究的总体质量较低,但 Redcore 洗剂联合咪康唑与咪康唑单独治疗相比,能显著提高临床疗效和安全性。